Anthony Traboulsee
Overview
Explore the profile of Anthony Traboulsee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
138
Citations
4297
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vavasour I, Elliott C, Arnold D, Gaetano L, Clayton D, Magon S, et al.
Mult Scler
. 2025 Feb;
:13524585251316519.
PMID: 39950257
Background: Multiple sclerosis (MS) slowly expanding lesions (SELs) are defined on magnetic resonance imaging (MRI) as contiguous regions of pre-existing focal non-contrast-enhancing T2 lesions with constant and concentric local expansion...
2.
Cerqueira J, Berthele A, Cree B, Filippi M, Pardo G, Pearson O, et al.
Neurology
. 2025 Jan;
104(4):e210142.
PMID: 39883906
Background And Objectives: Patients with multiple sclerosis (MS) may demonstrate better disease control when treatment is initiated on high-efficacy disease-modifying therapies (DMTs) from onset. This subgroup analysis assessed the long-term...
3.
Jia A, Kuramoto L, Khakban A, Sio W, Traboulsee A, De Vera M, et al.
BMJ Open
. 2025 Jan;
15(1):e088924.
PMID: 39855661
Introduction: Long-term population-based safety studies, applying advanced causal inference techniques, including an active comparator with new-user design, are needed to investigate skin cancer outcomes among individuals with multiple sclerosis (MS)...
4.
Keegan B, Absinta M, Cohen-Adad J, Flanagan E, Henry R, Klawiter E, et al.
Brain Commun
. 2024 Nov;
6(6):fcae395.
PMID: 39611182
Spinal cord disease is important in most people with multiple sclerosis, but assessment remains less emphasized in patient care, basic and clinical research and therapeutic trials. The North American Imaging...
5.
Oh J, Arbour N, Giuliani F, Guenette M, Kolind S, Lynd L, et al.
Ther Adv Neurol Disord
. 2024 Sep;
17:17562864241273045.
PMID: 39282637
Background: Disease progression is observed across the spectrum of people with multiple sclerosis (MS) and identification of effective treatment strategies to halt progression remains one of the greatest unmet clinical...
6.
Harrison D, Choi S, Bakshi R, Beck E, Callen A, Chu R, et al.
Hum Brain Mapp
. 2024 Aug;
45(12):e26816.
PMID: 39169546
Although 7 T MRI research has contributed much to our understanding of multiple sclerosis (MS) pathology, most prior data has come from small, single-center studies with varying methods. In order...
7.
Scalfari A, Traboulsee A, Oh J, Airas L, Bittner S, Calabrese M, et al.
Ann Neurol
. 2024 Jul;
96(5):826-845.
PMID: 39051525
Despite therapeutic suppression of relapses, multiple sclerosis (MS) patients often experience subtle deterioration, which extends beyond the definition of "progression independent of relapsing activity." We propose the concept of smouldering-associated-worsening...
8.
Traboulsee A, Li D
Neuroimaging Clin N Am
. 2024 Jun;
34(3):317-334.
PMID: 38942519
Standardized MR imaging protocols are important for the diagnosis and monitoring of patients with multiple sclerosis (MS) and the appropriate use of MR imaging in routine clinical practice. Advances in...
9.
Oh J, Bhan V, Traboulsee A, Morrow S, Lee L, Levin M, et al.
Can J Neurol Sci
. 2024 May;
:1-4.
PMID: 38777804
No abstract available.
10.
Greenfield J, Metz L, Khakban A, Llorian E, Michaux K, Traboulsee A, et al.
Mult Scler Relat Disord
. 2023 Nov;
80:105091.
PMID: 37924714
Background: Long-term population-based safety studies are needed to investigate cancer outcomes in people with multiple sclerosis (MS) treated with modern disease-modifying therapy (DMT). Objectives: To investigate if exposure to DMT...